US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Wag! Group Co

0.1400

+0.020016.67%

Volume:334.43K

Turnover:44.17K

Market Cap:7.10M

PE:-0.36

High:0.1400

Open:0.1210

Low:0.1210

Close:0.1200

Loading ...

Overview Company News Filings

Wag! Group Is Maintained at Buy by DA Davidson

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP

In Historic First, Origin Materials Announces Commencement of PET Cap Commercial Production

Imagion to start production of MagSense imaging agent for phase II breast cancer trial

Coca-Cola Warns Trump's Tariffs Could Force It to Use More Plastic – 'If Aluminium Cans Become More Expensive, We Can Shift to PET'

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Wag! Group Co expected to post a loss of 5 cents a share - Earnings Preview

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

LNTH: Evergreen Acquisition Promotes Future Innovation

Zacks Small Cap Research

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

The ASX biotechs aiming to catch cancer early

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher

Clarity jumps as FDA awards fast track status for PET scan imaging agent

The Market Herald

Guess which ASX 200 biotech stock is jumping 15% on big US FDA news

Press Release: ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

TriMas Packaging Group to Exhibit at Paris Packaging Week and LUXE PACK Los Angeles 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PET/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PET","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PET\",,,,,undefined,":{"symbol":"PET","market":"US","secType":"STK","nameCN":"Wag! Group Co","latestPrice":0.14,"timestamp":1744228800000,"preClose":0.12,"halted":0,"volume":334430,"delay":0,"floatShares":22064454,"shares":50733823,"eps":-0.392853,"marketStatus":"Pre-Market Trading","change":0.02,"latestTime":"04-10 06:31:42 EDT","open":0.121,"high":0.14,"low":0.121,"amount":44168.8657144,"amplitude":0.158333,"askPrice":0.1519,"askSize":100,"bidPrice":0.1052,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.392853,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744291800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1415,"postHourTrading":{"tag":"盘后","latestPrice":0.1428,"preClose":0.14,"latestTime":"19:59 EDT","volume":6759,"amount":1030.759,"timestamp":1744243169231},"volumeRatio":0.3125250728528074},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PET\",,,,,undefined,":{"symbol":"PET","floatShares":22064454,"roa":"-16.97%","roe":"-3036.82%","lyrEps":-0.392853,"volumeRatio":0.3125250728528074,"shares":50733823,"dividePrice":0,"high":0.14,"amplitude":0.158333,"preClose":0.12,"low":0.121,"week52Low":0.1035,"pbRate":"-14.53","psRate":"0.10","week52High":2.47,"institutionHeld":0,"latestPrice":0.14,"eps":-0.392853,"divideRate":0,"volume":334430,"delay":0,"ttmEps":-0.392853,"open":0.121,"prevYearClose":0.2383,"prevWeekClose":0.1113,"prevMonthClose":0.1531,"prevQuarterClose":0.1531,"fiveDayClose":0.12,"twentyDayClose":0.2447,"sixtyDayClose":0.243},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PET\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513261937","title":"Wag! Group Is Maintained at Buy by DA Davidson","url":"https://stock-news.laohu8.com/highlight/detail?id=2513261937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513261937?lang=en_us&edition=fundamental","pubTime":"2025-02-21 19:32","pubTimestamp":1740137520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PET/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 21, 2025 06:32 ET (11:32 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2513979258","title":"Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP","url":"https://stock-news.laohu8.com/highlight/detail?id=2513979258","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513979258?lang=en_us&edition=fundamental","pubTime":"2025-02-21 15:30","pubTimestamp":1740123000,"startTime":"0","endTime":"0","summary":"HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkk, Norway. Symrise will support the financing of the project through a EUR 5m loan. The partnership ideally complements both HBC and Symrise’s current portfolio with science-led, clinically proven marine ingredients for Consumer Health. HBC have also signed an exclusive distribution agreement for OmeGo, ProGo and NT-II into the Consumer Health and Functional Food categories for four of Symrise’s global key accounts.Hofseth BioCare ASA  today announced that it has signed a strategic partnership with Symrise, a global leader producing flavours, functional ingredients and solutions that enhance sensory properties and nutrition in a sustainable way. With this partnership, HBC and Symrise will expand its presence in the Health category with clinically proven marine ingredients. Symrise will ideally complement its current portfolio and through its loan, will accele","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hofseth-biocare-asa-hbc-accelerates-073000646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BERK","BK4234","BK4084","BK4142","ASA","BK4139","BGSX","MAR","HOFBF","BK4585","BK4192","PET","LU1718418525.SGD","BK4588","OUT"],"gpt_icon":0},{"id":"2512446400","title":"In Historic First, Origin Materials Announces Commencement of PET Cap Commercial Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2512446400","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512446400?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:00","pubTimestamp":1740052800,"startTime":"0","endTime":"0","summary":"— Origin CapFormer System 1 passes Site Acceptance Test and begins commercial production of PET closures —。WEST SACRAMENTO, Calif., February 20, 2025----Origin Materials  , a technology company with a mission to enable the world’s transition to sustainable materials, today announced that, in an historic first, Origin has commenced the commercial production of PET caps at our manufacturing center in Reed City, Michigan.\"Achieving this milestone is a tremendous accomplishment, and we couldn’t be prouder,\" said Origin CEO and Co-Founder John Bissell. \"Producing PET closures at commercial volumes, on the first Origin CapFormer System, in our production center in Michigan is just an awesome milestone in bringing our breakthrough caps to market.\". Bissell added: \"We are excited for what’s to come. Our manufacturing team and production partners in Michigan, Reed City Group, have been doing excellent work. Looking ahead, we expect to ramp the production volume of line 1 over time and with addi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/historic-first-origin-materials-announces-120000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORGN","BK4090","ARKG","BK4588","ORGNW","BK4544","BK4585","PET","BK4192"],"gpt_icon":0},{"id":"2512614503","title":"Imagion to start production of MagSense imaging agent for phase II breast cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512614503","media":"Stockheads","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512614503?lang=en_us&edition=fundamental","pubTime":"2025-02-19 10:18","pubTimestamp":1739931504,"startTime":"0","endTime":"0","summary":"Manufacturing to start on new batch of Imagion’s MagSense HER2 breast cancer imaging agent. The new batch intended for use in phase II study to be proposed to US FDA in an Investigational New Drug application. Imagion has previously made two batches of the imaging agent used in a phase I study on HER2+ breast cancer","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/2025-2-19-IBX-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/2025-2-19-IBX-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/imagion-to-start-production-of-magsense-imaging-agent-for-phase-ii-breast-cancer-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2512955689","title":"Coca-Cola Warns Trump's Tariffs Could Force It to Use More Plastic – 'If Aluminium Cans Become More Expensive, We Can Shift to PET'","url":"https://stock-news.laohu8.com/highlight/detail?id=2512955689","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512955689?lang=en_us&edition=fundamental","pubTime":"2025-02-16 23:30","pubTimestamp":1739719819,"startTime":"0","endTime":"0","summary":"Coca-Cola  is weighing a shift toward more plastic bottles in the U.S. as new aluminum tariffs threaten to drive up production costs.The 25% tariff, announced by President Donald Trump, takes effect on March 12 and applies to foreign steel and aluminum. Since Coca-Cola imports aluminum for its cans from Canada, the company is looking at ways to keep prices stable.\"If aluminum cans become more expensive, we can put more emphasis on PET bottles,\" Coca-Cola CEO James Quincey told investors in an earnings call this week. He acknowledged that packaging costs are just one part of the company's overall expenses but said rising aluminum prices still matter.Coca-Cola has been selling more drinks in aluminum cans in recent years as part of its sustainability efforts. Still, in 2023, nearly half  of its beverages were packaged in plastic, while aluminum and steel cans made up just 26%, according to the company's most recent environmental report.Environmental advocates argue that shifting away fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coca-cola-warns-trumps-tariffs-153019641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU2133065610.SGD","LU1116320901.HKD","IE00BDGV0183.EUR","LU0098860793.USD","LU2506952170.USD","BK4192","LU1868836757.USD","IE00BVYPNW00.USD","LU0868494617.USD","LU0265550359.USD","BK4504","LU1868837300.USD","LU1221951129.SGD","BK4533","LU1718418525.SGD","LU2237443549.SGD","IE00BGHQF631.EUR","BK4581","LU1868836591.USD","LU2506951875.HKD","LU2506951958.HKD","F","LU2125154935.USD","KO","LU0175139822.USD","SG9999014542.SGD","LU1221951046.USD","LU1894683348.USD","LU2237443382.USD","LU2279689827.SGD","LU1732800096.USD","LU2237443465.HKD","LU1670711040.USD","SG9999003800.SGD","LU1868836914.USD","LU2237443895.HKD","LU2237957902.USD","BK4588","IE00BVYPNV92.GBP","LU1670710588.SGD","LU2360032135.SGD","IE00BLSP4239.USD","LU0320765646.SGD","LU1162221912.USD","LU2264538146.SGD","PET","LU2506952097.USD","LU1732799900.SGD","SG9999014575.USD"],"gpt_icon":1},{"id":"2510371785","title":"Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371785","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371785?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:00","pubTimestamp":1739365200,"startTime":"0","endTime":"0","summary":"Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder. SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited  announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease in Clinical Pharmacology in Drug Development, the journal associated with the American College of Clinical Pharmacology.Actinogen Medical  is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.Actinogen is currently developing its lead compound, Xana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4192","BK4023","LU1169589451.USD","LU1169590202.USD","PET.AU","BK7067","BK4218","BK4181","PET","PK","PD","BK7508","BK7047","ACW.AU"],"gpt_icon":0},{"id":"2510857623","title":"Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues","url":"https://stock-news.laohu8.com/highlight/detail?id=2510857623","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510857623?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:32","pubTimestamp":1739194324,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics, Inc.  stock is trading lower on Monday.On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis , a chronic lung disease that causes scarring and stiffening of the lung tissue.Patients currently enrolled in BEACON-IPF will remain in the trial.The move follows a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board.In May 2024, On Tuesday,Pliant Therapeutics announced topline data from a Phase 2a PET Imaging trial ofbexotegrast evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis  characterized by excessive collagendeposition in the lung.Last February, Pliant Therapeutics released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pliant-therapeutics-pauses-lead-product-133204055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRX","PSC","SSI","PET","BK4139","BK4192","BK4007","LENZ"],"gpt_icon":0},{"id":"2509549741","title":"Wag! Group Co  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2509549741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509549741?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:21","pubTimestamp":1738938066,"startTime":"0","endTime":"0","summary":"Group Co  expected to post a loss of5cents a share - Earnings Preview Wag!Group Co PET.OQ PET.O is expected to show a fall in quarterly revenue when it reports  results on February 10  for the period ending December 31 2024The San Francisco California-based  company is expected to report a 12.8% decrease in revenue to $18.9 million from $21.67 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.LSEG's mean analyst estimate for Wag!Group Co is for a loss of 5 cents per share. The one available analyst rating on the shares is \"hold\".  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Wag!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nL8N3OY1K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2509286487","title":"Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2509286487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509286487?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:30","pubTimestamp":1738762200,"startTime":"0","endTime":"0","summary":"Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021190/0/en/Lantheus-Announces-Presentations-Featuring-PYLARIFY-Piflufolastat-F-18-Data-at-the-ASCO-GU-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4588","ADT","BK4192","BK4217","PET","BK4198","BK4585","LNTH","PSA","BK4165","BK4084"],"gpt_icon":0},{"id":"2507665906","title":"LNTH: Evergreen Acquisition Promotes Future Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2507665906","media":"Zacks Small Cap Research","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507665906?lang=en_us&edition=fundamental","pubTime":"2025-01-30 00:13","pubTimestamp":1738167180,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.  announced its second acquisition this month; this time for private company Evergreen Theragnostics for $250 million in cash plus milestones valued at $752.5 million. The company’s most advanced product, Octevy, is a positron emission tomography  diagnostic for certain neuroendocrine tumors  and could be a complementary imaging agent for Lantheus’ pipeline asset PNT2003. Octevy is being reviewed by the FDA and is expected to be approved in time for product commercialization in 2026. Evergreen has several other candidates in its pipeline with one in Phase II studies and the others in preclinical stages. Additional information was provided in a Form 8-K filing and webcast. The transaction is expected to be dilutive to earnings following closing due to research and development costs and launch related activities for Octevy. 18 months after close, the contribution of Life Molecular Imaging and Evergreen is expected to be accretive to earnings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lnth-evergreen-acquisition-promotes-future-161300658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","BK4198","PET","BK4192","LNTH","CDMO","BK4588"],"gpt_icon":0},{"id":"2506510566","title":"Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2506510566","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506510566?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:32","pubTimestamp":1738078330,"startTime":"0","endTime":"0","summary":"On Tuesday,Lantheus Holdings, Inc.  agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of$250 millionand up to an additional$752.5 millionin potential milestone payments.The acquisition also expands Lantheus’ oncology diagnostic pipeline by adding both OCTEVY, a registrational-stage PET diagnostic agent for certain neuroendocrine tumors  that could complement Lantheus’ therapeutic candidate PNT2003, as well as several clinical and pre-clinical novel theranostic pairs.The transaction is expected to close in the second half of 2025.The company also reaffirmed its fiscal year 2024 revenue guidance of $1.51 billion—$1.52 billion and adjusted EPS of $6.65-$6.70, compared to consensus of $1.52 billion and $6.74, respectively.Last week, Lantheus agreed to acquire Life Molecular Imaging in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lantheus-buy-evergreen-theragnostics-over-153210738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4198","CDMO","LNTH","BK4588","BK4192","PET","BK4585"],"gpt_icon":0},{"id":"2506224519","title":"Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2506224519","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506224519?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:04","pubTimestamp":1738073040,"startTime":"0","endTime":"0","summary":"Two abstracts on Clarity's diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium  2025.An abstract on the COBRA study has also been selected for presentation at the American Urological Association  Annual Meeting 2025.In a subset of participants in the COBRA study who underwent follow-up SOC PSMA PET, 70% of participants had a positive scan on same-day imaging and 90% on next-day imaging using 64Cu-SAR-bisPSMA, compared to 60% of participants using SOC PSMA PET where only same-day imaging is possible. The number of lesions across all participants  identified by 64Cu-SAR-bisPSMA was also higher  than that detected by SOC PET agents . Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents. Across all participants in the study, histopathology confirmed the presence of prostate cancer in lesions iden","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-present-cobra-clarify-abstracts-140400147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0724618433.USD","AUA.AU","LU2357305700.SGD","LU1861220033.SGD","SOC","BK4192","BK7001","IE00BZ199S13.USD","LU2298322129.HKD","LU1548497426.USD","TGA.AU","LU2360107325.USD","LU1854103824.USD","LU1861219969.SGD","TGA","BCR","BK7003","LU1720051017.SGD","LU1854104046.USD","BK7047","BK4135","ON","LU1720051108.HKD","LU1861214812.USD","LU1861215975.USD","BK4585","BK4141","BK4588","LU0124384867.USD","SAR","BK4213","IE00BD6J9T35.USD","CU6.AU","BK4512","PET","SAR.AU","BK7061","LU0348723411.USD","BK7096","LU1978683503.SGD","SOC.AU","PET.AU"],"gpt_icon":0},{"id":"2506962591","title":"Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2506962591","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506962591?lang=en_us&edition=fundamental","pubTime":"2025-01-28 19:00","pubTimestamp":1738062000,"startTime":"0","endTime":"0","summary":"Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY, a registrational-stage diagnostic asset, ta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016192/0/en/Lantheus-to-Acquire-Evergreen-Theragnostics-for-Upfront-Payment-of-250-Million-to-Drive-Strategic-Evolution-into-Fully-Integrated-Radiopharmaceutical-Leader.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","PET","BK4585","EPM","BK4213","BK4588","CDMO","BK4192","BK4198","BK4139"],"gpt_icon":0},{"id":"2506835325","title":"The ASX biotechs aiming to catch cancer early","url":"https://stock-news.laohu8.com/highlight/detail?id=2506835325","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506835325?lang=en_us&edition=fundamental","pubTime":"2025-01-27 17:06","pubTimestamp":1737968779,"startTime":"0","endTime":"0","summary":"Early detection and treatment can improve prognosis for cancer patients. Several ASX biotechs looking to improve early cancer diagnostics and medical treatment. Optiscan’s technology brings surgeons and pathologists together to facilitate earlier cancer detection and treatment","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/1200x675-9-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/1200x675-9-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/the-asx-biotechs-aiming-to-catch-cancer-early/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["PET","BK4192"],"gpt_icon":0},{"id":"2505865344","title":"Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505865344","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505865344?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:02","pubTimestamp":1737727320,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of an FTD for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1]. These 2 FTDs enable the Company to accelerate the development of its comprehensive diagnostic program with this product.The FDA's FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For 64Cu-SAR-bisPSMA, it provides a number of product development advantages. The designation paves the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-u-fda-fast-140200877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["SOC","IE00BYQQ9H92.USD","BK4192","BK7001","TGA.AU","TGA","BCR","BK7047","BK4135","FAST","IE00BFXG0V08.USD","BK4585","BK4588","BK4567","SAR","BK4213","CU6.AU","PET","IE00B5TLWC47.USD","SAR.AU","BK7061","BK7096","BK4104","SOC.AU","PET.AU"],"gpt_icon":0},{"id":"2505074824","title":"Why Clarity, Genesis Energy, IGO, and Wesfarmers shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074824?lang=en_us&edition=fundamental","pubTime":"2025-01-24 09:29","pubTimestamp":1737682171,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index  is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,410.4 points.Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:. The Clarity Pharmaceuticals share price is up 3.5% to $4.20. This follows news that the U.S. Food and Drug Administration  has granted Fast Track Designation  for 64Cu-SAR-bisPSMA. This is for positron emission tomography  imaging of prostate-specific membrane antigen  positive prostate cancer lesions in patients with biochemical recurrence  of prostate cancer following definitive therapy. Clarity executive chair, Dr Alan Taylor, said: \"Receiving the second FTD for 64Cu-SAR-bisPSMA and well within the 60-day period following our application submission, reserved by the U.S. FDA for review, is yet another significant milestone in our bisPSMA program.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/why-clarity-genesis-energy-igo-and-wesfarmers-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4588","TLC.AU","IE0034235188.USD","LU0106831901.USD","IE0004086264.USD","PLS.AU","BK7506","PET","BK7153","IE0002270589.USD","BK7047","WES.AU","BK4127","LU1668664300.SGD","IE0004091025.USD","BK4552","LU2237443382.USD","BK7507","PET.AU","BK7078","XJO.AU","BK7041","BK7006","BK4192","BK4585","BK4533","BCR","BK4550","BK7095","BK4504","IE00BFXG1179.USD","LU2237443622.USD","LU1791807156.HKD","LU2237443549.SGD","IE00B19Z3B42.SGD","LU2237443895.HKD","GNE.AU","BK7511","LU2237443465.HKD","BK7096","BK7504","IGO.AU","CU6.AU","IE00BSNM7G36.USD","LU2237438978.USD","LU2237443978.SGD","BK4516","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2505600298","title":"Clarity jumps as FDA awards fast track status for PET scan imaging agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2505600298","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505600298?lang=en_us&edition=fundamental","pubTime":"2025-01-24 08:47","pubTimestamp":1737679620,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer.The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen the company’s price climb to as much as $8/sh over the last six months.One-year returns are up 84%, but just a few months ago, were far higher. Source: TradingView. Clarity’s market cap currently sits above $1 billion, seeing it join a class of companies on the ASX in biotech undergoing something of a boom.While Clarity’s announcement it’s received fast-track status from the FDA for its copper-based Cu-64 SAR-bisPSMA imaging agent doesn’t reflect a full approval for use in the U.S., it does underscore regulator interest in the agent.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/clarity-jumps-as-fda-awards-fast-track-status-for-pet-scan-imaging-agent-2025-01-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CU6.AU","BK4192","BK7096","PET"],"gpt_icon":0},{"id":"2505107139","title":"Guess which ASX 200 biotech stock is jumping 15% on big US FDA news","url":"https://stock-news.laohu8.com/highlight/detail?id=2505107139","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505107139?lang=en_us&edition=fundamental","pubTime":"2025-01-24 07:58","pubTimestamp":1737676722,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd  shares are ending the week on a high. In early trade, the ASX 200 biotech stock was up as much as 15% to $4.69. Its shares have since pulled back but remain up 3% to $4.19 at the time of writing. Why is this ASX 200 biotech stock jumping?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/24/guess-which-asx-200-biotech-stock-is-jumping-15-on-big-us-fda-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4192","BCR","PET.AU","PET","BK7096","CU6.AU","BK7047"],"gpt_icon":0},{"id":"2505779030","title":"Press Release: ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2505779030","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505779030?lang=en_us&edition=fundamental","pubTime":"2025-01-23 01:55","pubTimestamp":1737568500,"startTime":"0","endTime":"0","summary":"ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery. INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited .Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology. In addition, ImaginAb will continue to partner in advancing the pivotal prostate cancer imaging agent, which is currently being evaluated in Phase 2 clinical trials and as a surgical resection tool.Jefferies LLC and Stifel, Nicolau","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSD","TLX.AU","BK7067","PET","BK4192"],"gpt_icon":0},{"id":"2505272521","title":"TriMas Packaging Group to Exhibit at Paris Packaging Week and LUXE PACK Los Angeles 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505272521","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505272521?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:00","pubTimestamp":1737471600,"startTime":"0","endTime":"0","summary":"BLOOMFIELD HILLS, Mich., January 21, 2025----TriMas Packaging, the largest operating group of TriMas , is excited to announce its participation in two upcoming trade shows, where the Company will showcase its diverse portfolio of innovative and sustainable dispensing and closure product solutions.TriMas Packaging will be attending the following trade shows:. TriMas Packaging serves its global customers with its market-leading brands, consisting of Rieke, Affaba & Ferrari, Rapak, Taplast, Plastic Srl and Aarts Packaging. TriMas Packaging designs and manufactures a comprehensive array of dispensing, closure and flexible packaging solutions for a broad range of end markets including the beauty and personal care, food and beverage, home care, pharmaceutical and nutraceutical, and industrial and agricultural markets. With approximately 2,200 dedicated employees and 26 locations worldwide, TriMas Packaging’s innovative solutions and services are designed to enhance customers’ ability to disp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trimas-packaging-group-exhibit-paris-150000035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PET","LU0128526141.USD","TRS","BK4136","PACK","LU0029874061.USD","BK4192","PP","BK4126"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":122,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PET\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"PET","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2024-11-13","symbol":"PET","fiscalQuarterEnding":"2024/09","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2024-08-07","symbol":"PET","fiscalQuarterEnding":"2024/06","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.06},{"date":"2024-07-10","symbol":"PET","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1720598400000,"name":null,"time":"Pre-Market","dateTimestamp":1720584000000,"actualEps":null},{"market":"US","date":"2024-05-09","symbol":"PET","fiscalQuarterEnding":"2024/03","expectedEps":-0.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PET\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PET\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1731643200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PET\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PET","date":"2025-04-09","current":-0.346542,"percent":0.997672,"low":-51.918761,"twenty":-24.608818,"median":-4.631011,"eighty":-1.901454,"high":-0.321418,"avg":-10.313156,"sd":10.935605,"marketCap":6088058},"quantilePoints":[{"date":"2021-10-01","current":-7.916755,"twenty":-7.916755,"median":-7.908627,"eighty":-7.901458,"marketCap":149143750},{"date":"2021-10-08","current":-7.941139,"twenty":-7.942895,"median":-7.928947,"eighty":-7.908627,"marketCap":149603125},{"date":"2021-10-15","current":-7.900499,"twenty":-7.941172,"median":-7.916755,"eighty":-7.900499,"marketCap":148837500},{"date":"2021-10-22","current":-7.908627,"twenty":-7.941139,"median":-7.908627,"eighty":-7.900499,"marketCap":148990625},{"date":"2021-10-29","current":-7.908627,"twenty":-7.934637,"median":-7.908627,"eighty":-7.900499,"marketCap":148990625},{"date":"2021-11-05","current":-7.941139,"twenty":-7.941139,"median":-7.916755,"eighty":-7.900499,"marketCap":149603125},{"date":"2021-11-12","current":-7.949267,"twenty":-7.941139,"median":-7.924883,"eighty":-7.907001,"marketCap":149756250},{"date":"2021-11-19","current":-7.965524,"twenty":-7.949267,"median":-7.933011,"eighty":-7.908627,"marketCap":150062500},{"date":"2021-11-26","current":-8.185579,"twenty":-7.949267,"median":-7.933011,"eighty":-7.908627,"marketCap":154208125},{"date":"2021-12-03","current":-8.143943,"twenty":-7.965524,"median":-7.941139,"eighty":-7.908627,"marketCap":153423750},{"date":"2021-12-10","current":-8.110635,"twenty":-8.123958,"median":-7.941139,"eighty":-7.908627,"marketCap":152796250},{"date":"2021-12-17","current":-8.111634,"twenty":-8.143943,"median":-7.941139,"eighty":-7.908627,"marketCap":152815075},{"date":"2021-12-23","current":-8.135616,"twenty":-8.143943,"median":-7.949267,"eighty":-7.908627,"marketCap":153266875},{"date":"2021-12-31","current":-8.143943,"twenty":-8.143943,"median":-7.949267,"eighty":-7.911878,"marketCap":153423750},{"date":"2022-01-07","current":-25.77251,"twenty":-8.143943,"median":-7.957396,"eighty":-7.916755,"marketCap":153423750},{"date":"2022-01-14","current":-25.746157,"twenty":-8.168925,"median":-7.965524,"eighty":-7.916755,"marketCap":153266875},{"date":"2022-01-21","current":-25.746157,"twenty":-8.185579,"median":-7.977716,"eighty":-7.918381,"marketCap":153266875},{"date":"2022-01-28","current":-25.746157,"twenty":-25.693453,"median":-8.111634,"eighty":-7.924883,"marketCap":153266875},{"date":"2022-02-04","current":-25.825214,"twenty":-25.746157,"median":-8.115298,"eighty":-7.926509,"marketCap":153737500},{"date":"2022-02-11","current":-25.956975,"twenty":-25.746157,"median":-8.135616,"eighty":-7.933011,"marketCap":154521875},{"date":"2022-02-18","current":-25.904271,"twenty":-25.746157,"median":-8.143943,"eighty":-7.933011,"marketCap":154208125},{"date":"2022-02-25","current":-25.851566,"twenty":-25.77251,"median":-8.143943,"eighty":-7.933011,"marketCap":153894375},{"date":"2022-03-04","current":-25.930623,"twenty":-25.77251,"median":-8.143943,"eighty":-7.933011,"marketCap":154365000},{"date":"2022-03-11","current":-25.956975,"twenty":-25.825214,"median":-8.143943,"eighty":-7.941139,"marketCap":154521875},{"date":"2022-03-18","current":-26.115089,"twenty":-25.825214,"median":-8.160598,"eighty":-7.941139,"marketCap":155463125},{"date":"2022-03-25","current":-26.036032,"twenty":-25.851566,"median":-8.177252,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-01","current":-26.036032,"twenty":-25.877919,"median":-8.185579,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-08","current":-26.036032,"twenty":-25.904271,"median":-16.939516,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-14","current":-26.220498,"twenty":-25.956975,"median":-25.700041,"eighty":-7.941139,"marketCap":156090625},{"date":"2022-04-22","current":-26.036032,"twenty":-25.956975,"median":-25.746157,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-29","current":-26.088737,"twenty":-26.00968,"median":-25.746157,"eighty":-7.941269,"marketCap":155306250},{"date":"2022-05-06","current":-26.036032,"twenty":-26.01495,"median":-25.746157,"eighty":-7.947674,"marketCap":154992500},{"date":"2022-05-13","current":-24.509388,"twenty":-26.01495,"median":-25.746157,"eighty":-7.949267,"marketCap":154678750},{"date":"2022-05-20","current":-24.534246,"twenty":-26.00968,"median":-25.746157,"eighty":-7.949267,"marketCap":154835625},{"date":"2022-05-27","current":-24.68339,"twenty":-26.00968,"median":-25.719805,"eighty":-7.949267,"marketCap":155776875},{"date":"2022-06-03","current":-24.68339,"twenty":-26.00968,"median":-25.693453,"eighty":-7.949267,"marketCap":155776875},{"date":"2022-06-10","current":-24.583961,"twenty":-26.00968,"median":-24.68339,"eighty":-7.954144,"marketCap":155149375},{"date":"2022-06-17","current":-24.608818,"twenty":-26.00968,"median":-24.68339,"eighty":-7.957396,"marketCap":155306250},{"date":"2022-06-24","current":-24.708248,"twenty":-25.988598,"median":-24.68339,"eighty":-7.960647,"marketCap":155933750},{"date":"2022-07-01","current":-24.608818,"twenty":-25.956975,"median":-24.658533,"eighty":-7.965524,"marketCap":155306250},{"date":"2022-07-08","current":-24.733105,"twenty":-25.956975,"median":-24.658533,"eighty":-7.96715,"marketCap":156090625},{"date":"2022-07-15","current":-24.757962,"twenty":-25.956975,"median":-24.68339,"eighty":-7.975278,"marketCap":156247500},{"date":"2022-07-22","current":-24.807677,"twenty":-25.956975,"median":-24.68339,"eighty":-8.007551,"marketCap":156561250},{"date":"2022-07-29","current":-25.105966,"twenty":-25.956975,"median":-24.68339,"eighty":-8.110835,"marketCap":158443750},{"date":"2022-08-05","current":-19.587625,"twenty":-25.956975,"median":-24.68339,"eighty":-8.111634,"marketCap":123617500},{"date":"2022-08-12","current":-46.571248,"twenty":-25.956975,"median":-24.68339,"eighty":-8.111634,"marketCap":293911149},{"date":"2022-08-19","current":-31.187311,"twenty":-26.00968,"median":-24.68339,"eighty":-8.1131,"marketCap":196823120},{"date":"2022-08-26","current":-29.685032,"twenty":-26.00968,"median":-24.708248,"eighty":-8.118962,"marketCap":187342238},{"date":"2022-09-02","current":-34.550721,"twenty":-26.036032,"median":-24.733105,"eighty":-8.122293,"marketCap":159278826},{"date":"2022-09-09","current":-42.365766,"twenty":-26.036032,"median":-24.757962,"eighty":-8.135616,"marketCap":195306179},{"date":"2022-09-16","current":-44.175565,"twenty":-26.036032,"median":-24.78282,"eighty":-8.135616,"marketCap":203649356},{"date":"2022-09-23","current":-20.154587,"twenty":-26.036032,"median":-24.78282,"eighty":-8.143943,"marketCap":92912648},{"date":"2022-09-30","current":-16.864043,"twenty":-26.036032,"median":-24.745534,"eighty":-8.143943,"marketCap":77743236},{"date":"2022-10-07","current":-20.812696,"twenty":-26.036032,"median":-24.733105,"eighty":-8.143943,"marketCap":95946530},{"date":"2022-10-14","current":-24.020978,"twenty":-26.036032,"median":-24.708248,"eighty":-8.143943,"marketCap":110736707},{"date":"2022-10-21","current":-32.45159,"twenty":-26.036032,"median":-24.733105,"eighty":-8.143943,"marketCap":149601831},{"date":"2022-10-28","current":-34.873351,"twenty":-26.036032,"median":-24.745534,"eighty":-8.143943,"marketCap":160766146},{"date":"2022-11-04","current":-27.317458,"twenty":-26.115089,"median":-24.78282,"eighty":-8.143943,"marketCap":125933481},{"date":"2022-11-11","current":-2.304056,"twenty":-26.115089,"median":-24.78282,"eighty":-8.143943,"marketCap":108509519},{"date":"2022-11-18","current":-2.038504,"twenty":-26.115089,"median":-24.757962,"eighty":-8.143943,"marketCap":96003337},{"date":"2022-11-25","current":-1.9604,"twenty":-26.115089,"median":-24.733105,"eighty":-8.132285,"marketCap":92325048},{"date":"2022-12-02","current":-1.991642,"twenty":-26.094007,"median":-24.708248,"eighty":-8.111634,"marketCap":93796364},{"date":"2022-12-09","current":-1.62846,"twenty":-26.046573,"median":-24.68339,"eighty":-7.972026,"marketCap":76692321},{"date":"2022-12-16","current":-1.679227,"twenty":-26.036032,"median":-24.68339,"eighty":-7.95577,"marketCap":79083209},{"date":"2022-12-23","current":-2.436832,"twenty":-26.036032,"median":-24.658533,"eighty":-7.949267,"marketCap":114762610},{"date":"2022-12-30","current":-2.405591,"twenty":-26.036032,"median":-24.658533,"eighty":-7.941139,"marketCap":113291295},{"date":"2023-01-06","current":-2.069667,"twenty":-26.036032,"median":-24.633675,"eighty":-7.941139,"marketCap":97470974},{"date":"2023-01-13","current":-2.218142,"twenty":-26.036032,"median":-24.621246,"eighty":-7.933011,"marketCap":104463401},{"date":"2023-01-20","current":-2.17128,"twenty":-26.036032,"median":-24.608818,"eighty":-7.926509,"marketCap":102256428},{"date":"2023-01-27","current":-2.530556,"twenty":-26.036032,"median":-24.608818,"eighty":-7.916755,"marketCap":119176557},{"date":"2023-02-03","current":-2.155659,"twenty":-26.036032,"median":-24.608818,"eighty":-7.908627,"marketCap":101520770},{"date":"2023-02-10","current":-1.851055,"twenty":-26.036032,"median":-24.608818,"eighty":-7.902125,"marketCap":87175444},{"date":"2023-02-17","current":-1.874486,"twenty":-26.036032,"median":-24.571532,"eighty":-7.893997,"marketCap":88278931},{"date":"2023-02-24","current":-2.245322,"twenty":-26.036032,"median":-24.559103,"eighty":-2.530556,"marketCap":86595328},{"date":"2023-03-03","current":-2.245322,"twenty":-26.036032,"median":-24.534246,"eighty":-2.452453,"marketCap":86595328},{"date":"2023-03-10","current":-1.614721,"twenty":-26.036032,"median":-24.534246,"eighty":-2.413401,"marketCap":62274938},{"date":"2023-03-17","current":-1.94913,"twenty":-26.036032,"median":-24.534246,"eighty":-2.38997,"marketCap":75172115},{"date":"2023-03-24","current":-2.197549,"twenty":-26.036032,"median":-24.509388,"eighty":-2.340867,"marketCap":84752874},{"date":"2023-03-31","current":-2.140222,"twenty":-26.036032,"median":-24.020978,"eighty":-2.293095,"marketCap":82541930},{"date":"2023-04-06","current":-2.111558,"twenty":-26.036032,"median":-23.445132,"eighty":-2.245322,"marketCap":81436457},{"date":"2023-04-14","current":-2.159331,"twenty":-26.036032,"median":-22.561,"eighty":-2.225952,"marketCap":83278911},{"date":"2023-04-21","current":-2.203009,"twenty":-26.01495,"median":-21.964387,"eighty":-2.217056,"marketCap":84963432},{"date":"2023-04-28","current":-2.270943,"twenty":-26.00968,"median":-20.697308,"eighty":-2.210332,"marketCap":87583450},{"date":"2023-05-05","current":-2.021661,"twenty":-26.00968,"median":-19.99006,"eighty":-2.209686,"marketCap":77969386},{"date":"2023-05-12","current":-2.248784,"twenty":-26.00968,"median":-19.907797,"eighty":-2.209686,"marketCap":89960352},{"date":"2023-05-19","current":-2.248784,"twenty":-26.00968,"median":-19.587625,"eighty":-2.209686,"marketCap":89960352},{"date":"2023-05-26","current":-1.874257,"twenty":-26.00968,"median":-19.301764,"eighty":-2.197549,"marketCap":74977784},{"date":"2023-06-02","current":-2.174138,"twenty":-25.978057,"median":-18.097997,"eighty":-2.197549,"marketCap":86974229},{"date":"2023-06-09","current":-2.061683,"twenty":-25.956975,"median":-16.864043,"eighty":-2.186237,"marketCap":82475562},{"date":"2023-06-16","current":-2.127282,"twenty":-25.956975,"median":-8.185579,"eighty":-2.180933,"marketCap":85099784},{"date":"2023-06-23","current":-2.04294,"twenty":-25.956975,"median":-8.185579,"eighty":-2.17128,"marketCap":81725784},{"date":"2023-06-29","current":-1.958599,"twenty":-25.956975,"median":-8.185579,"eighty":-2.164767,"marketCap":78351784},{"date":"2023-07-07","current":-1.883628,"twenty":-25.956975,"median":-8.168925,"eighty":-2.16347,"marketCap":75352672},{"date":"2023-07-14","current":-1.893,"twenty":-25.956975,"median":-8.148107,"eighty":-2.155659,"marketCap":75727561},{"date":"2023-07-21","current":-2.04294,"twenty":-25.956975,"median":-8.143943,"eighty":-2.147849,"marketCap":81725784},{"date":"2023-07-28","current":-2.108539,"twenty":-25.956975,"median":-8.143943,"eighty":-2.139508,"marketCap":84350007},{"date":"2023-08-04","current":-2.267851,"twenty":-25.941164,"median":-8.143943,"eighty":-2.138794,"marketCap":90723118},{"date":"2023-08-11","current":-2.32208,"twenty":-25.920074,"median":-8.135616,"eighty":-2.137501,"marketCap":99345563},{"date":"2023-08-18","current":-2.075795,"twenty":-25.907779,"median":-8.118962,"eighty":-2.137501,"marketCap":88808739},{"date":"2023-08-25","current":-2.053134,"twenty":-25.904271,"median":-8.111634,"eighty":-2.127997,"marketCap":87839211},{"date":"2023-09-01","current":-1.840115,"twenty":-25.904271,"median":-8.046207,"eighty":-2.121113,"marketCap":78725651},{"date":"2023-09-08","current":-1.903567,"twenty":-25.903322,"median":-7.973652,"eighty":-2.112829,"marketCap":81440328},{"date":"2023-09-15","current":-1.758534,"twenty":-25.899527,"median":-7.965524,"eighty":-2.108539,"marketCap":75235351},{"date":"2023-09-22","current":-1.695082,"twenty":-25.877919,"median":-7.953331,"eighty":-2.093176,"marketCap":72520673},{"date":"2023-09-29","current":-1.740405,"twenty":-25.851566,"median":-7.949267,"eighty":-2.080425,"marketCap":74459729},{"date":"2023-10-06","current":-1.704146,"twenty":-25.851566,"median":-7.945284,"eighty":-2.069745,"marketCap":72908484},{"date":"2023-10-13","current":-1.676952,"twenty":-25.851566,"median":-7.941139,"eighty":-2.061683,"marketCap":71745051},{"date":"2023-10-20","current":-1.60933,"twenty":-25.851566,"median":-7.941139,"eighty":-2.052312,"marketCap":68851980},{"date":"2023-10-27","current":-1.568177,"twenty":-25.851566,"median":-7.941139,"eighty":-2.045204,"marketCap":67091318},{"date":"2023-11-03","current":-1.560563,"twenty":-25.851566,"median":-7.933011,"eighty":-2.038504,"marketCap":66765557},{"date":"2023-11-10","current":-16.478139,"twenty":-25.851566,"median":-7.933011,"eighty":-2.036475,"marketCap":66703507},{"date":"2023-11-17","current":-17.055401,"twenty":-25.841025,"median":-7.941139,"eighty":-2.038504,"marketCap":69040264},{"date":"2023-11-24","current":-17.063157,"twenty":-25.825214,"median":-7.941139,"eighty":-2.038504,"marketCap":69071661},{"date":"2023-12-01","current":-17.063157,"twenty":-25.825214,"median":-7.941139,"eighty":-2.039391,"marketCap":69071661},{"date":"2023-12-08","current":-16.966208,"twenty":-25.825214,"median":-7.949267,"eighty":-2.04294,"marketCap":68679208},{"date":"2023-12-15","current":-16.869258,"twenty":-25.825214,"median":-7.949267,"eighty":-2.04294,"marketCap":68286755},{"date":"2023-12-22","current":-17.257057,"twenty":-25.819944,"median":-7.957396,"eighty":-2.044072,"marketCap":69856566},{"date":"2023-12-29","current":-16.966208,"twenty":-25.804132,"median":-7.96146,"eighty":-2.047469,"marketCap":68679208},{"date":"2024-01-05","current":-17.063157,"twenty":-25.798862,"median":-7.965524,"eighty":-2.050085,"marketCap":69071661},{"date":"2024-01-12","current":-16.384509,"twenty":-25.798862,"median":-8.046207,"eighty":-2.052312,"marketCap":66324492},{"date":"2024-01-19","current":-17.450956,"twenty":-25.793592,"median":-8.111634,"eighty":-2.052312,"marketCap":70641471},{"date":"2024-01-26","current":-19.293002,"twenty":-25.77251,"median":-8.118962,"eighty":-2.052476,"marketCap":78098071},{"date":"2024-02-02","current":-19.370562,"twenty":-25.77251,"median":-8.135616,"eighty":-2.054844,"marketCap":78412033},{"date":"2024-02-09","current":-17.935705,"twenty":-25.77251,"median":-8.143943,"eighty":-2.061683,"marketCap":72603734},{"date":"2024-02-16","current":-6.45394,"twenty":-25.77251,"median":-8.143943,"eighty":-2.06328,"marketCap":85947123},{"date":"2024-02-23","current":-5.95295,"twenty":-25.77251,"median":-8.139779,"eighty":-2.069667,"marketCap":79275429},{"date":"2024-03-01","current":-5.894009,"twenty":-25.77251,"median":-8.118962,"eighty":-2.069745,"marketCap":78490524},{"date":"2024-03-08","current":-6.33606,"twenty":-25.746157,"median":-8.111634,"eighty":-2.069745,"marketCap":84377313},{"date":"2024-03-15","current":-6.12977,"twenty":-25.746157,"median":-8.110635,"eighty":-2.075795,"marketCap":81630144},{"date":"2024-03-22","current":-5.894009,"twenty":-25.746157,"median":-7.969588,"eighty":-2.077556,"marketCap":78490524},{"date":"2024-03-28","current":-5.658249,"twenty":-25.746157,"median":-7.96146,"eighty":-2.077556,"marketCap":75350903},{"date":"2024-04-05","current":-6.089301,"twenty":-25.746157,"median":-7.949267,"eighty":-2.079851,"marketCap":81091218},{"date":"2024-04-12","current":-6.392251,"twenty":-25.746157,"median":-7.949267,"eighty":-2.080425,"marketCap":85125607},{"date":"2024-04-19","current":-6.301366,"twenty":-25.746157,"median":-7.941302,"eighty":-2.084378,"marketCap":83915291},{"date":"2024-04-26","current":-6.664906,"twenty":-25.746157,"median":-7.941139,"eighty":-2.091032,"marketCap":88756558},{"date":"2024-05-03","current":-6.831529,"twenty":-25.746157,"median":-7.941139,"eighty":-2.093031,"marketCap":90975471},{"date":"2024-05-10","current":-7.133641,"twenty":-25.746157,"median":-7.937075,"eighty":-2.09797,"marketCap":98237372},{"date":"2024-05-17","current":-5.947142,"twenty":-25.746157,"median":-7.933011,"eighty":-2.099168,"marketCap":81898096},{"date":"2024-05-24","current":-4.687403,"twenty":-25.735616,"median":-7.924883,"eighty":-2.106665,"marketCap":64550224},{"date":"2024-05-31","current":-4.572017,"twenty":-25.71717,"median":-7.916755,"eighty":-2.108539,"marketCap":62961251},{"date":"2024-06-07","current":-4.572017,"twenty":-25.698723,"median":-7.908627,"eighty":-2.108539,"marketCap":62961251},{"date":"2024-06-14","current":-4.513024,"twenty":-25.693453,"median":-7.908627,"eighty":-2.108642,"marketCap":62148847},{"date":"2024-06-21","current":-4.365539,"twenty":-25.580927,"median":-7.908627,"eighty":-2.109349,"marketCap":60117839},{"date":"2024-06-28","current":-4.92598,"twenty":-25.355875,"median":-7.908627,"eighty":-2.110454,"marketCap":67835670},{"date":"2024-07-05","current":-4.719502,"twenty":-25.12088,"median":-7.900499,"eighty":-2.114099,"marketCap":64992259},{"date":"2024-07-12","current":-4.45403,"twenty":-24.996593,"median":-7.900499,"eighty":-2.119192,"marketCap":61336444},{"date":"2024-07-15","current":-4.719502,"twenty":-24.941907,"median":-7.900499,"eighty":-2.119832,"marketCap":64992259},{"date":"2024-08-02","current":-3.480633,"twenty":-24.88722,"median":-7.896435,"eighty":-2.120473,"marketCap":47931791},{"date":"2024-08-09","current":-3.44267,"twenty":-24.832534,"median":-7.872782,"eighty":-2.121113,"marketCap":41838766},{"date":"2024-08-16","current":-3.734947,"twenty":-24.812648,"median":-6.984832,"eighty":-2.126048,"marketCap":45390806},{"date":"2024-08-23","current":-3.084343,"twenty":-24.807677,"median":-6.876972,"eighty":-2.127282,"marketCap":37484020},{"date":"2024-08-30","current":-3.413661,"twenty":-24.787791,"median":-6.869398,"eighty":-2.127282,"marketCap":41486221},{"date":"2024-09-06","current":-3.375508,"twenty":-24.78282,"median":-6.801234,"eighty":-2.127997,"marketCap":41022551},{"date":"2024-09-13","current":-2.972696,"twenty":-24.767905,"median":-6.725496,"eighty":-2.129789,"marketCap":36127177},{"date":"2024-09-20","current":-3.449806,"twenty":-24.757962,"median":-6.635604,"eighty":-2.134259,"marketCap":41925487},{"date":"2024-09-27","current":-3.545388,"twenty":-24.743048,"median":-6.543726,"eighty":-2.136653,"marketCap":43087101},{"date":"2024-10-04","current":-3.48595,"twenty":-24.733105,"median":-6.48341,"eighty":-2.137501,"marketCap":42364752},{"date":"2024-10-11","current":-3.353821,"twenty":-24.733105,"median":-6.45394,"eighty":-2.13936,"marketCap":40758992},{"date":"2024-10-18","current":-3.413661,"twenty":-24.718191,"median":-6.392251,"eighty":-2.140222,"marketCap":41486221},{"date":"2024-10-25","current":-3.226914,"twenty":-24.708248,"median":-6.361956,"eighty":-2.143518,"marketCap":39216680},{"date":"2024-10-31","current":-2.961451,"twenty":-24.708248,"median":-6.331661,"eighty":-2.146569,"marketCap":35990517},{"date":"2024-11-08","current":-2.552615,"twenty":-24.698305,"median":-6.303978,"eighty":-2.147849,"marketCap":31021931},{"date":"2024-11-15","current":-0.547386,"twenty":-24.68339,"median":-6.27712,"eighty":-2.146569,"marketCap":8878051},{"date":"2024-11-22","current":-0.606003,"twenty":-24.68339,"median":-6.22989,"eighty":-2.137218,"marketCap":9828767},{"date":"2024-11-29","current":-0.659113,"twenty":-24.68339,"median":-6.184448,"eighty":-2.128912,"marketCap":10690153},{"date":"2024-12-06","current":-0.685514,"twenty":-24.68339,"median":-6.12977,"eighty":-2.122347,"marketCap":11118357},{"date":"2024-12-13","current":-0.70639,"twenty":-24.678419,"median":-6.080065,"eighty":-2.109349,"marketCap":11456936},{"date":"2024-12-20","current":-0.621353,"twenty":-24.658533,"median":-6.04136,"eighty":-2.101042,"marketCap":10077722},{"date":"2024-12-27","current":-0.728186,"twenty":-24.658533,"median":-6.035031,"eighty":-2.092449,"marketCap":11810453},{"date":"2025-01-03","current":-0.874929,"twenty":-24.658533,"median":-6.01189,"eighty":-2.079851,"marketCap":14190469},{"date":"2025-01-10","current":-0.83195,"twenty":-24.658533,"median":-5.968121,"eighty":-2.073375,"marketCap":13493393},{"date":"2025-01-17","current":-0.801251,"twenty":-24.643618,"median":-5.93531,"eighty":-2.061683,"marketCap":12995482},{"date":"2025-01-24","current":-0.788664,"twenty":-24.633675,"median":-5.894009,"eighty":-2.052312,"marketCap":12791338},{"date":"2025-01-31","current":-0.791427,"twenty":-24.633675,"median":-5.894009,"eighty":-2.04294,"marketCap":12836150},{"date":"2025-02-07","current":-0.997726,"twenty":-24.623732,"median":-5.776129,"eighty":-2.038504,"marketCap":16182114},{"date":"2025-02-14","current":-1.099033,"twenty":-24.608818,"median":-5.658249,"eighty":-2.027617,"marketCap":17825220},{"date":"2025-02-21","current":-0.92282,"twenty":-24.608818,"median":-5.628779,"eighty":-2.021458,"marketCap":14967210},{"date":"2025-02-28","current":-0.775463,"twenty":-24.608818,"median":-5.099654,"eighty":-1.992156,"marketCap":12577236},{"date":"2025-03-07","current":-0.775156,"twenty":-24.608818,"median":-4.778496,"eighty":-1.977341,"marketCap":12572257},{"date":"2025-03-14","current":-0.75643,"twenty":-24.608818,"median":-4.719502,"eighty":-1.959028,"marketCap":12268531},{"date":"2025-03-21","current":-0.722967,"twenty":-24.608818,"median":-4.719502,"eighty":-1.953792,"marketCap":11725808},{"date":"2025-03-28","current":-0.540029,"twenty":-24.608818,"median":-4.704754,"eighty":-1.94913,"marketCap":9487224},{"date":"2025-04-04","current":-0.369934,"twenty":-24.608818,"median":-4.631011,"eighty":-1.92291,"marketCap":6499002},{"date":"2025-04-09","current":-0.346542,"twenty":-24.608818,"median":-4.631011,"eighty":-1.901454,"marketCap":6088058}],"updateTime":1744281102946}}}